CAR-NK Cell Therapy Platform
Oncology
Preclinical/Clinical DevelopmentActive
Key Facts
About CytoImmune Therapeutics
CytoImmune Therapeutics is a private, clinical-stage biotech focused on developing off-the-shelf CAR-NK cell therapies for cancer. The company's core strength lies in its proprietary NK cell engineering platform, built upon decades of foundational research from its scientific founders, Drs. Caligiuri and Yu. With a seasoned leadership team experienced in cell therapy CMC and commercialization, and an in-house manufacturing capability, CytoImmune is positioned to advance allogeneic NK cell therapies through clinical development. Its strategy targets the significant limitations of current autologous CAR-T treatments, such as manufacturing complexity and patient accessibility.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |